Lv3
360 积分 2024-02-17 加入
Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy
3小时前
待确认
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
2天前
已完结
Bortezomib plus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 Trial
2天前
已完结
Adverse outcomes and high incidence of therapy-related neoplasms in patients with the t(16;21)/ RUNX1 :: RUNX1T3 fusion
4个月前
已完结
Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphoma
5个月前
已完结
Enasidenib plus venetoclax in patients with IDH2-mutated relapsed or refractory acute myeloid leukaemia or myelodysplastic syndrome (ENAVEN-AML): a multicentre, single-arm, phase 1b/2 trial
5个月前
已完结
Old drug, new use: Recent advances for G-CSF
6个月前
已完结
A wearable osmotic microneedle patch provides high-capacity sustained drug delivery in animal models
8个月前
已完结
Dynamic evolution of venetoclax resistance in acute myeloid leukemia unveiled by longitudinal single-cell RNA-seq
8个月前
已完结
Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial
9个月前
已关闭
皖公网安备34019202002308
